한글목차

세계의 HPV 검사 및 자궁경부암 검사 시장 규모는 2024년에 42억 6,000만 달러로 평가되었고, 2030년에는 80억 1,000만 달러에 이를 것으로 예측되며, 예측 기간 중의 CAGR은 11.10%를 보일 것으로 전망됩니다.

이 시장은 전 세계 의료 시스템이 여성 건강과 자궁경부암 예방에 더 많은 관심을 기울이면서 견고한 성장을 보이고 있습니다. 자궁경부암의 주요 원인인 인유두종 바이러스(HPV)는 HPV 검사 및 세포진 검사 등 조기 발견 도구에 대한 수요를 주도하고 있습니다. 대중의 인식 제고, 정부의 검사 프로그램, 그리고 민감도와 진단 정확도를 높인 HPV DNA 검사 및 액체 기반 세포학 등의 기술 혁신이 시장 성장을 뒷받침하고 있습니다. 이러한 발전은 조기 발견을 강화하고 위음성률을 낮추며 환자 치료 결과를 개선합니다. 의료 투자 확대, 현장 진료 방식을 통한 선별 검사 접근성 확대, 예방적 건강 조치의 우선순위화도 크게 기여하고 있습니다. 코로나19 팬데믹은 효율적이고 확장 가능한 진단 솔루션의 채택을 더욱 가속화하여 글로벌 의료 시스템에서 신뢰할 수 있는 검사 도구의 가치를 강화했습니다.

시장 성장 촉진요인

자궁경부암 발병률 및 사망률 증가

주요 시장 과제

의료 서비스에 대한 제한된 접근성

주요 시장 동향

HPV DNA 검사의 급속한 채택

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 HPV 검사 및 자궁경부암 검사 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 검사 유형별(HPV 검사, 자궁경부암 검사, 공동 검사)
  • 용도별(자궁 경부암 검사, 두경부암 검사, 기타)
  • 최종 사용자별(병원 및 진료소, 진단 센터, 현장 진료 및 자가 샘플링)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 HPV 검사 및 자궁경부암 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 HPV 검사 및 자궁경부암 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 HPV 검사 및 자궁경부암 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 HPV 검사 및 자궁경부암 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 HPV 검사 및 자궁경부암 검사 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Arbor Vita Corporation
• Danaher Corporation
• Seegene Inc.
• Becton, Dickinson and Company
• TruScreen
• Abbott Laboratories
• Hologic Inc.
• Qiagen NV
• F. Hoffmann-La Roche Ltd
• OncoHealth Corporation

제16장 전략적 제안

제17장 기업 소개와 면책사항

영문목차

The Global HPV Testing and Pap Test Market was valued at USD 4.26 billion in 2024 and is projected to reach USD 8.01 billion by 2030, growing at a CAGR of 11.10% during the forecast period. This market is witnessing robust expansion as healthcare systems around the world focus more on women's health and the prevention of cervical cancer. Human Papillomavirus (HPV), a primary cause of cervical cancer, has driven demand for early detection tools such as HPV testing and Pap smears. Market growth is being supported by rising public awareness, government screening programs, and technological innovations like HPV DNA testing and liquid-based cytology, which offer higher sensitivity and improved diagnostic accuracy. These advancements enhance early detection, reduce false negatives, and improve patient outcomes. Increasing healthcare investments, expanding screening access through point-of-care methods, and the prioritization of preventive health measures are also contributing significantly. The COVID-19 pandemic further accelerated the adoption of efficient and scalable diagnostic solutions, reinforcing the value of reliable testing tools in global healthcare systems.

Key Market Drivers

Rising Cervical Cancer Incidence and Mortality Rates

The growing incidence of cervical cancer, especially in low- and middle-income countries, is a primary factor driving the demand for HPV and Pap testing. Many of these regions face high mortality rates due to late diagnoses and limited access to routine screenings. According to the WHO, in 2020, around 604,000 women were diagnosed with cervical cancer globally, with 342,000 deaths. Given that a majority of these cases are linked to HPV infections, early screening using HPV tests and Pap smears has become vital. Governments and health organizations are expanding screening programs to address this urgent public health issue, with efforts ranging from public education campaigns to infrastructure development and subsidized testing services. The increasing focus on early detection as a means of reducing cervical cancer mortality is expected to significantly boost the adoption of HPV and Pap tests across diverse healthcare settings.

Key Market Challenges

Limited Access to Healthcare Services

Access to healthcare services remains a significant barrier to the widespread adoption of HPV and Pap testing, particularly in underserved and rural areas. In many regions, inadequate healthcare infrastructure, limited medical personnel, long travel distances to healthcare facilities, and affordability issues prevent regular screenings. Women in these settings are often unable to receive timely diagnostic evaluations, increasing the risk of undetected cervical abnormalities progressing to cancer. These systemic challenges reduce overall screening rates and limit the effectiveness of national and global cancer prevention efforts. Addressing these access issues is essential for ensuring that life-saving tests reach the populations most at risk.

Key Market Trends

Rapid Adoption of HPV DNA Testing

The increasing use of HPV DNA testing is a major trend reshaping the HPV and Pap test market. This advanced method offers superior sensitivity and specificity in identifying high-risk HPV strains that are most likely to cause cervical cancer. As awareness of its diagnostic advantages grows, healthcare providers are increasingly integrating HPV DNA tests into routine screening protocols. This trend is further accelerated by the rising demand for early and accurate detection tools, especially in preventive oncology. The shift towards HPV DNA testing is enhancing the reliability of screening programs and contributing to better patient outcomes by identifying risk at an earlier stage.

Key Market Players

• Arbor Vita Corporation
• Danaher Corporation
• Seegene Inc.
• Becton, Dickinson and Company
• TruScreen
• Abbott Laboratories
• Hologic Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche Ltd
• OncoHealth Corporation

Report Scope:

In this report, the Global HPV Testing and Pap Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HPV Testing and Pap Test Market, By Test Type:

• HPV Test
• Pap Test
• Co-testing

HPV Testing and Pap Test Market, By End User:

• Hospitals/Clinics
• Diagnostic Centers
• Point-of-Care/Self-sampling

HPV Testing and Pap Test Market, By Application:

• Cervical Cancer Screening Test
• Head and Neck Cancer Screening Test
• Other Applications

HPV Testing and Pap Test Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HPV Testing and Pap Test Market.

Available Customizations:

Global HPV Testing and Pap Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global HPV Testing and Pap Test Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (HPV Test, Pap Test, Co-testing)
  • 5.2.2. By Application (Cervical Cancer Screening Test, Head and Neck Cancer Screening Test, Other Applications)
  • 5.2.3. By End User (Hospitals/Clinics, Diagnostic Centers, Point-of-Care/Self-sampling)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America HPV Testing and Pap Test Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States HPV Testing and Pap Test Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico HPV Testing and Pap Test Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada HPV Testing and Pap Test Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe HPV Testing and Pap Test Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France HPV Testing and Pap Test Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany HPV Testing and Pap Test Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom HPV Testing and Pap Test Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy HPV Testing and Pap Test Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain HPV Testing and Pap Test Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific HPV Testing and Pap Test Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China HPV Testing and Pap Test Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India HPV Testing and Pap Test Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea HPV Testing and Pap Test Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan HPV Testing and Pap Test Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia HPV Testing and Pap Test Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America HPV Testing and Pap Test Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil HPV Testing and Pap Test Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina HPV Testing and Pap Test Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia HPV Testing and Pap Test Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa HPV Testing and Pap Test Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa HPV Testing and Pap Test Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia HPV Testing and Pap Test Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE HPV Testing and Pap Test Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Arbor Vita Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Seegene Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. TruScreen
• 15.6. Abbott Laboratories
• 15.7. Hologic Inc.
• 15.8. Qiagen N.V.
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. OncoHealth Corporation

16. Strategic Recommendation

17. About Us & Disclaimer